- Home
- GLTO vs SGD Comparison
GLTO vs SGD Comparison
Compare GLTO & SGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- SGD
- Stock Information
- Founded
- GLTO 2011
- SGD 2021
- Country
- GLTO Denmark
- SGD United States
- Employees
- GLTO N/A
- SGD N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- SGD
- Sector
- GLTO Health Care
- SGD
- Exchange
- GLTO Nasdaq
- SGD Nasdaq
- Market Cap
- GLTO 4.5M
- SGD 4.4M
- IPO Year
- GLTO 2020
- SGD N/A
- Fundamental
- Price
- GLTO $2.87
- SGD $1.32
- Analyst Decision
- GLTO Buy
- SGD
- Analyst Count
- GLTO 1
- SGD 0
- Target Price
- GLTO $10.00
- SGD N/A
- AVG Volume (30 Days)
- GLTO 241.8K
- SGD 1.4M
- Earning Date
- GLTO 10-31-2025
- SGD 08-15-2025
- Dividend Yield
- GLTO N/A
- SGD N/A
- EPS Growth
- GLTO N/A
- SGD N/A
- EPS
- GLTO N/A
- SGD N/A
- Revenue
- GLTO N/A
- SGD $1,536,255.00
- Revenue This Year
- GLTO N/A
- SGD N/A
- Revenue Next Year
- GLTO N/A
- SGD N/A
- P/E Ratio
- GLTO N/A
- SGD N/A
- Revenue Growth
- GLTO N/A
- SGD 1570.24
- 52 Week Low
- GLTO $2.01
- SGD $0.65
- 52 Week High
- GLTO $14.82
- SGD $6.25
- Technical
- Relative Strength Index (RSI)
- GLTO 40.87
- SGD 54.46
- Support Level
- GLTO $2.45
- SGD $1.02
- Resistance Level
- GLTO $3.99
- SGD $1.80
- Average True Range (ATR)
- GLTO 0.28
- SGD 0.15
- MACD
- GLTO -0.03
- SGD 0.02
- Stochastic Oscillator
- GLTO 27.27
- SGD 49.47
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.